Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Gross Margin (2020 - 2025)

BridgeBio Pharma (BBIO) has disclosed Gross Margin for 6 consecutive years, with 94.74% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 3017.0% to 94.74% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 95.82% through Dec 2025, down 243.0% year-over-year, with the annual reading at 95.82% for FY2025, 243.0% down from the prior year.
  • Gross Margin hit 94.74% in Q4 2025 for BridgeBio Pharma, roughly flat from 94.56% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.72% in Q1 2024 to a low of 118.64% in Q3 2022.
  • Historically, Gross Margin has averaged 69.14% across 5 years, with a median of 81.3% in 2021.
  • Biggest five-year swings in Gross Margin: crashed -15661bps in 2022 and later surged 20402bps in 2023.
  • Year by year, Gross Margin stood at 84.49% in 2021, then fell by -23bps to 65.4% in 2022, then grew by 1bps to 65.73% in 2023, then fell by -2bps to 64.57% in 2024, then soared by 47bps to 94.74% in 2025.
  • Business Quant data shows Gross Margin for BBIO at 94.74% in Q4 2025, 94.56% in Q3 2025, and 96.7% in Q2 2025.